Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Abatacept for Delay of Type 1 Diabetes

In patients at risk for progression from normal glucose tolerance (NGT) to abnormal glucose tolerance (AGT), abatacept therapy for 1 year significantly impacted immune cell subsets and preserved insulin secretion, but progression to AGT was not significantly delayed, a study shows.

Participants in the phase 2 randomized controlled trial were antibody-positive and had NGT. Monthly infusions of abatacept or placebo for 12 months had these effects on an endpoint of AGT or diabetes as assessed by oral glucose tolerance tests: “A total of 101 participants received abatacept and 111 placebo. Of these, 81 (35 abatacept and 46 placebo) met the endpoint of AGT or type 1 diabetes diagnosis (hazard ratio 0.702; 95% CI 0.452, 1.09; P = 0.11) The C-peptide responses to oral glucose tolerance tests were higher in the abatacept arm (P < 0.03). Abatacept reduced the frequency of inducible T-cell costimulatory (ICOS)+ PD1+ T-follicular helper (Tfh) cells during treatment (P < 0.0001), increased naïve CD4+ T cells, and also reduced the frequency of CD4+ regulatory T cells (Tregs) from the baseline (P = 0.0067). Twelve months after treatment, the frequency of ICOS+ Tfh, naïve CD4+ T cells, and Tregs returned to baseline.”

Source: Diabetes Care